Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib in SETD2-Deficient Advanced Solid Tumors
NCT03284385Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adavosertib in solid tumor, clear cell renal cell carcinoma (ccRCC), sponsored by National Cancer Institute. Started Jan 2019; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03284385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284385.